In addition to providing revised and updated recommendations on the use of secondary preventive therapies after CABG, this statement highlights areas in need of prospectively collected clinical trial data. Comprehensive risk factor management reduces risk as assessed by a variety of outcomes, including improved sur- vival, reduced recurrent events, the need for revasculariza- tion procedures, and improved quality of life. It is important not only that the healthcare providers implement these rec- ommendations in appropriate CABG patients but also that healthcare systems support this implementation to maximize the benefit to the patient. In this scientific statement, clas- sifications of recommendations and levels of evidence are expressed in AHA/ACCF format, as detailed in the Table. Recommendations made herein are based largely on recent clinical and observational trials and major practice guide- lines previously published by the AHA/ACCF and the National Institutes of Health. Thus, the development of the present statement involved a process of partial adaptation of other guideline statements and reports and supplemental lit- erature searches. 2015 American Heart Association, Inc. Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000182 TheAmerican HeartAssociation makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on December 5, 2014. A copy of the document is available at http://my.americanheart.org/statements by selecting either the By Topic link or the By Publication Date link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com. 